European Heart Journal vs Blood: Which Journal Should You Choose?

EHJ asks whether the result matters across cardiology. Blood asks whether the result matters across hematology.

That distinction is more useful than any prestige comparison.

EHJ's editorial guidance keep returning to field-wide cardiovascular significance, practice consequence, and general cardiology readership. Blood's editorial guidance keep returning to broad hematology relevance, complete mechanistic stories, and work that matters beyond one narrow disease or assay niche.

So if your paper becomes stronger when written as a general cardiology manuscript, EHJ is more realistic. If it becomes stronger when written for hematologists, Blood is more realistic.

EHJ wins when the cardiovascular story dominates.

That usually means:

• the main consequence is about cardiovascular outcomes, risk, or management
• the practical audience is cardiologists
• the hematologic context matters, but the core message still lives in cardiology
• the paper belongs in a broad cardiovascular conversation rather than a hematology conversation

Examples:

• thrombosis studies where the real implication is cardiovascular management
• cardio-oncology or coagulation papers where the result should change how cardiologists interpret treatment risk
• cardiovascular-outcome work in hematologic populations when the core consequence isn't disease-specific hematology practice

Blood wins when the hematology story dominates.

That includes:

• coagulation and platelet papers that matter broadly to hematologists
• translational blood-disease studies with clear hematologic consequence
• hematologic malignancy or blood-disorder papers where cardiovascular findings are important, but still secondary
• mechanistic or clinical blood research where the real readership is inside hematology

Blood's editorial guidance are especially clear that the journal wants research about blood cells or hematologic disorders, not general biology or general medicine that happens to touch blood.

Blood strongly rewards complete hematology stories

Blood submission's editorial guidance emphasizes complete mechanistic stories, functional validation, and manuscripts that close meaningful hematology questions rather than merely opening them.

EHJ strongly rewards broad cardiovascular consequence

EHJ's editorial guidance make clear that narrow specialist stories, even strong ones, struggle if they don't matter across cardiology.

Blood is less interested in cardiovascular relevance unless it matters to hematology

A thrombosis or coagulation paper isn't automatically a Blood paper. The result still has to contribute to hematology, not only to cardiovascular management.

EHJ is less interested in hematology depth unless it matters to cardiologists

The fact that a study is biologically rich or hematologically important doesn't by itself make it suitable for a broad cardiology flagship.

• the manuscript is fundamentally cardiovascular
• cardiologists are the main audience
• the main implication is cardiovascular interpretation, prevention, or management
• the paper feels strongest as a cardiology paper

That's the EHJ lane.

• the manuscript is fundamentally hematologic
• hematologists are the main audience
• the work matters broadly across blood biology or hematologic disease
• the paper feels strongest as a hematology paper

That's the Blood lane.

Thrombosis and coagulation papers

These are the most obvious overlap zone. If the paper is mainly about cardiovascular management or cardiology-facing decision-making, EHJ can make sense. If the paper is mainly about coagulation biology, thrombosis mechanisms, or broad hematology consequence, Blood is often more natural.

Platelet biology with clinical consequences

Again, the question isn't whether both fields care. It's which field has to act first. If the paper changes hematology interpretation, Blood gets stronger. If it changes cardiology practice more broadly, EHJ becomes more realistic.

Cardio-oncology toxicity in hematologic treatment

Some of these papers can go either way. The audience test still decides it. If the main message is how hematology or oncology teams should think about treatment consequences, Blood is more plausible. If the main message is how cardiologists should manage risk and outcomes, EHJ is more plausible.

This can be a real cascade, but only when the audience was wrong.

A paper rejected by EHJ can move to Blood if:

• the work is genuinely hematology-led
• the rejection reflected insufficient breadth for cardiology
• the manuscript is still strong enough for a flagship hematology journal

The reverse route is less common. A paper rejected by Blood because it lacks enough hematologic relevance doesn't usually become an EHJ paper unless the cardiovascular consequence was the real center of gravity all along.

EHJ punishes narrow disease-lane manuscripts

If the paper only feels important once the reader is already inside a hematology problem, EHJ often becomes the wrong room.

Blood punishes weak hematologic identity

Blood's editorial guidance make clear that papers using blood cells or coagulation as a convenient model don't fit well unless the work truly answers a hematologic question.

EHJ punishes specialty logic disguised as general significance

If the manuscript's claim to broad cardiology importance feels inflated, that usually shows quickly.

Blood punishes incomplete mechanistic or translational stories

Especially in basic and translational work, the journal wants completeness, not just interesting directionality.

A strong EHJ first page tells a cardiology editor why the result matters across cardiovascular medicine before specialty detail takes over.

A strong Blood first page tells a hematology editor why the result matters broadly across hematology before the cardiovascular crossover angle takes over.

If only one of those openings feels natural, that's usually the better journal.

Try finishing one of these sentences:

• "this changes what cardiologists should do or how they stratify cardiovascular risk" points toward European Heart Journal
• "this changes what hematologists should do or how they interpret blood disease biology" points toward Blood

That sentence test is simple, but it's often enough.

Some authors assume that any thrombosis, coagulation, or cardio-oncology manuscript automatically belongs in whichever journal has the higher cardiovascular profile. That isn't how editors read these papers.

A good Blood paper can be deeply important without being a general cardiology paper. A good EHJ paper can involve blood biology or coagulation without being a hematology paper. Once you see that difference clearly, the targeting decision usually gets much easier.

Send to European Heart Journal first if:

1. the manuscript is fundamentally cardiovascular
2. cardiologists are the practical audience
3. the paper has broad cardiovascular consequence
4. the hematologic context supports the story, but doesn't define it

Send to Blood first if:

1. the manuscript is fundamentally hematologic
2. hematologists are the practical audience
3. the paper matters broadly across hematology
4. cardiovascular findings are important, but still inside a blood-disease or coagulation story